Clinical observation of aprepitant for prevention of nausea and vomiting induced by platinum?based chemotherapy in lung cancer patients

LI Shenke; AN Tongtong

doi:10.3969/j.issn.1009-0460.2017.01.015

Abstract：Objective To evaluate the efficacy and tolerance of aprepitant on the prevention of nausea and vomiting induced by platinum?based chemotherapy in the treatment of patients with lung cancer. Methods A total of 44 cases of patients with lung cancer treated by platinum?based chemotherapy enrolled from January 2014 to December 2014 in Department of Thoracic Oncology, Beijing Canc?er Hospital. Self?control comparative study on the antiemetic efficacy of aprepitant used or not in the chemotherapy was performed. At the same time, the maintenance of antiemetic effect of aprepitant was evaluated in multiple chemotherapy cycles. Results The incidence of acute nausea and vomiting of granisetron and dexamethasone was 500%, while the incidence of delayed nausea and vomiting was 818%. The incidence of acute nausea and vomiting of aprepitant, granisetron and dexamethasone was 250%, while the incidence of delayed nausea and vomiting was 477%. The effective control rate of acute nausea and vomiting of aprepitant, granisetron and dexamethasone was 909%;while the effective control rate of delayed nausea and vomiting was 778%. The antiemetic effect of aprepitant was better in mul?tiple chemotherapy cycles without significant difference. The main adverse reactions and their incidences caused by Aprepitant were ano?rexia, fatigue, constipation and diarrhea, respectively. These adverse reactions except for anorexia had significant differences before and after chemotherapy( P<005) through self?control comparative analysis. Conclusion Aprepitant can effectively reduce the incidence of a?cute and delayed nausea and vomiting caused by platinum?based chemotherapy and the adverse reactions were tolerable.